Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study.

Choong-Kun LeeJii Bum LeeSe Jung ParkJingmin CheWoo Sun KwonHyo Song KimMinkyu JungSeulkee LeeSook Ryun ParkDong-Hoe KooHyun Woo LeeWoo Kyun BaeHei-Cheul JeungIn Gyu HwangHyunki KimChung Mo NamHyun Cheol ChungSun Young Rha

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2023)

Although the study did not meet its primary end point, nivolumab and paclitaxel for AGC demonstrated a durable response with manageable toxicity profiles. Genomic analysis or plasma cytokine analysis may provide information for the selection of patients who would benefit more from immunotherapy combined with chemotherapy.

Keyphrases

oxidative stress
healthcare
clinical trial
radiation therapy
locally advanced
lymph node
chemotherapy induced